?>
Plan Name | PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN |
Plan identification number | 001 |
401k Plan Type | Defined Contribution Pension |
Plan Features/Benefits |
|
Company Name: | PPD, INC. |
Employer identification number (EIN): | 561640186 |
NAIC Classification: | 325410 |
Additional information about PPD, INC.
Jurisdiction of Incorporation: | Texas Secretary of State |
Incorporation Date: | 1991-06-26 |
Company Identification Number: | 0008796506 |
Legal Registered Office Address: |
300 INDUSTRY DR PITTSBURGH United States of America (USA) 15275 |
More information about PPD, INC.
Plan id# | Filing Submission Date | Name of Administrator | Date Administrator Signed | Name of Company Sponsor | Date Sponsor Signed |
---|---|---|---|---|---|
001 | 2022-01-01 | ||||
001 | 2021-01-01 | ||||
001 | 2020-01-01 | ||||
001 | 2019-01-01 | ||||
001 | 2018-01-01 | ||||
001 | 2017-01-01 | EVAN RENNEKER | |||
001 | 2016-01-01 | DEBRA MORELAND | |||
001 | 2015-01-01 | DEBRA MORELAND | |||
001 | 2014-01-01 | DEBRA J MORELAND | |||
001 | 2013-01-01 | DEBRA J MORELAND | BRIAN S TUTTLE | 2014-10-15 | |
001 | 2012-01-01 | DEBRA MORELAND | BRIAN TUTTLE | 2013-09-30 | |
001 | 2011-01-01 | DEBRA J MORELAND | BRIAN TUTTLE | 2012-09-28 | |
001 | 2009-01-01 | DEBRA MORELAND |
Measure | Date | Value |
---|---|---|
2022: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2022 401k membership | ||
Total participants, beginning-of-year | 2022-01-01 | 17,082 |
Total number of active participants reported on line 7a of the Form 5500 | 2022-01-01 | 15,886 |
Number of retired or separated participants receiving benefits | 2022-01-01 | 33 |
Number of other retired or separated participants entitled to future benefits | 2022-01-01 | 3,481 |
Total of all active and inactive participants | 2022-01-01 | 19,400 |
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits | 2022-01-01 | 11 |
Total participants | 2022-01-01 | 19,411 |
Number of participants with account balances | 2022-01-01 | 16,539 |
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested | 2022-01-01 | 1,279 |
2021: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2021 401k membership | ||
Total participants, beginning-of-year | 2021-01-01 | 14,092 |
Total number of active participants reported on line 7a of the Form 5500 | 2021-01-01 | 14,003 |
Number of retired or separated participants receiving benefits | 2021-01-01 | 26 |
Number of other retired or separated participants entitled to future benefits | 2021-01-01 | 3,043 |
Total of all active and inactive participants | 2021-01-01 | 17,072 |
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits | 2021-01-01 | 10 |
Total participants | 2021-01-01 | 17,082 |
Number of participants with account balances | 2021-01-01 | 14,282 |
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested | 2021-01-01 | 767 |
2020: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2020 401k membership | ||
Total participants, beginning-of-year | 2020-01-01 | 12,799 |
Total number of active participants reported on line 7a of the Form 5500 | 2020-01-01 | 11,350 |
Number of retired or separated participants receiving benefits | 2020-01-01 | 11 |
Number of other retired or separated participants entitled to future benefits | 2020-01-01 | 2,719 |
Total of all active and inactive participants | 2020-01-01 | 14,080 |
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits | 2020-01-01 | 12 |
Total participants | 2020-01-01 | 14,092 |
Number of participants with account balances | 2020-01-01 | 11,241 |
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested | 2020-01-01 | 592 |
2019: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2019 401k membership | ||
Total participants, beginning-of-year | 2019-01-01 | 11,583 |
Total number of active participants reported on line 7a of the Form 5500 | 2019-01-01 | 10,122 |
Number of retired or separated participants receiving benefits | 2019-01-01 | 27 |
Number of other retired or separated participants entitled to future benefits | 2019-01-01 | 2,496 |
Total of all active and inactive participants | 2019-01-01 | 12,645 |
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits | 2019-01-01 | 11 |
Total participants | 2019-01-01 | 12,656 |
Number of participants with account balances | 2019-01-01 | 10,135 |
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested | 2019-01-01 | 531 |
2018: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2018 401k membership | ||
Total participants, beginning-of-year | 2018-01-01 | 11,113 |
Total number of active participants reported on line 7a of the Form 5500 | 2018-01-01 | 9,130 |
Number of retired or separated participants receiving benefits | 2018-01-01 | 27 |
Number of other retired or separated participants entitled to future benefits | 2018-01-01 | 2,297 |
Total of all active and inactive participants | 2018-01-01 | 11,454 |
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits | 2018-01-01 | 11 |
Total participants | 2018-01-01 | 11,465 |
Number of participants with account balances | 2018-01-01 | 9,103 |
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested | 2018-01-01 | 546 |
2017: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2017 401k membership | ||
Total participants, beginning-of-year | 2017-01-01 | 10,474 |
Total number of active participants reported on line 7a of the Form 5500 | 2017-01-01 | 8,703 |
Number of retired or separated participants receiving benefits | 2017-01-01 | 26 |
Number of other retired or separated participants entitled to future benefits | 2017-01-01 | 2,322 |
Total of all active and inactive participants | 2017-01-01 | 11,051 |
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits | 2017-01-01 | 9 |
Total participants | 2017-01-01 | 11,060 |
Number of participants with account balances | 2017-01-01 | 8,729 |
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested | 2017-01-01 | 441 |
2016: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2016 401k membership | ||
Total participants, beginning-of-year | 2016-01-01 | 9,786 |
Total number of active participants reported on line 7a of the Form 5500 | 2016-01-01 | 8,291 |
Number of retired or separated participants receiving benefits | 2016-01-01 | 16 |
Number of other retired or separated participants entitled to future benefits | 2016-01-01 | 2,117 |
Total of all active and inactive participants | 2016-01-01 | 10,424 |
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits | 2016-01-01 | 10 |
Total participants | 2016-01-01 | 10,434 |
Number of participants with account balances | 2016-01-01 | 7,985 |
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested | 2016-01-01 | 414 |
2015: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2015 401k membership | ||
Total participants, beginning-of-year | 2015-01-01 | 10,719 |
Total number of active participants reported on line 7a of the Form 5500 | 2015-01-01 | 7,747 |
Number of retired or separated participants receiving benefits | 2015-01-01 | 16 |
Number of other retired or separated participants entitled to future benefits | 2015-01-01 | 2,017 |
Total of all active and inactive participants | 2015-01-01 | 9,780 |
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits | 2015-01-01 | 6 |
Total participants | 2015-01-01 | 9,786 |
Number of participants with account balances | 2015-01-01 | 7,327 |
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested | 2015-01-01 | 404 |
2014: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2014 401k membership | ||
Total participants, beginning-of-year | 2014-01-01 | 8,314 |
Total number of active participants reported on line 7a of the Form 5500 | 2014-01-01 | 8,903 |
Number of retired or separated participants receiving benefits | 2014-01-01 | 15 |
Number of other retired or separated participants entitled to future benefits | 2014-01-01 | 1,795 |
Total of all active and inactive participants | 2014-01-01 | 10,713 |
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits | 2014-01-01 | 6 |
Total participants | 2014-01-01 | 10,719 |
Number of participants with account balances | 2014-01-01 | 6,706 |
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested | 2014-01-01 | 334 |
2013: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2013 401k membership | ||
Total participants, beginning-of-year | 2013-01-01 | 7,813 |
Total number of active participants reported on line 7a of the Form 5500 | 2013-01-01 | 6,657 |
Number of retired or separated participants receiving benefits | 2013-01-01 | 11 |
Number of other retired or separated participants entitled to future benefits | 2013-01-01 | 1,642 |
Total of all active and inactive participants | 2013-01-01 | 8,310 |
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits | 2013-01-01 | 4 |
Total participants | 2013-01-01 | 8,314 |
Number of participants with account balances | 2013-01-01 | 6,481 |
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested | 2013-01-01 | 248 |
2012: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2012 401k membership | ||
Total participants, beginning-of-year | 2012-01-01 | 7,335 |
Total number of active participants reported on line 7a of the Form 5500 | 2012-01-01 | 6,397 |
Number of retired or separated participants receiving benefits | 2012-01-01 | 10 |
Number of other retired or separated participants entitled to future benefits | 2012-01-01 | 1,626 |
Total of all active and inactive participants | 2012-01-01 | 8,033 |
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits | 2012-01-01 | 3 |
Total participants | 2012-01-01 | 8,036 |
Number of participants with account balances | 2012-01-01 | 6,168 |
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested | 2012-01-01 | 219 |
2011: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2011 401k membership | ||
Total participants, beginning-of-year | 2011-01-01 | 7,343 |
Total number of active participants reported on line 7a of the Form 5500 | 2011-01-01 | 5,956 |
Number of retired or separated participants receiving benefits | 2011-01-01 | 8 |
Number of other retired or separated participants entitled to future benefits | 2011-01-01 | 1,806 |
Total of all active and inactive participants | 2011-01-01 | 7,770 |
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits | 2011-01-01 | 2 |
Total participants | 2011-01-01 | 7,772 |
Number of participants with account balances | 2011-01-01 | 6,117 |
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested | 2011-01-01 | 221 |
2009: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2009 401k membership | ||
Total participants, beginning-of-year | 2009-01-01 | 7,796 |
Total number of active participants reported on line 7a of the Form 5500 | 2009-01-01 | 5,688 |
Number of retired or separated participants receiving benefits | 2009-01-01 | 5 |
Number of other retired or separated participants entitled to future benefits | 2009-01-01 | 1,758 |
Total of all active and inactive participants | 2009-01-01 | 7,451 |
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits | 2009-01-01 | 4 |
Total participants | 2009-01-01 | 7,455 |
Number of participants with account balances | 2009-01-01 | 6,032 |
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested | 2009-01-01 | 308 |
Measure | Date | Value |
---|---|---|
2022 : PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2022 401k financial data | ||
Unrealized appreciation/depreciation of real estate assets | 2022-12-31 | $0 |
Unrealized appreciation/depreciation of other (non real estate) assets | 2022-12-31 | $0 |
Total unrealized appreciation/depreciation of assets | 2022-12-31 | $0 |
Total transfer of assets to this plan | 2022-12-31 | $0 |
Total transfer of assets from this plan | 2022-12-31 | $3,558 |
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2022-12-31 | $0 |
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2022-12-31 | $0 |
Expenses. Interest paid | 2022-12-31 | $0 |
Amount of participant contributions which was failed to transmit to the plan within the time period described in 29 CFR 251.3-102 | 2022-12-31 | $0 |
Total income from all sources (including contributions) | 2022-12-31 | $-55,486,004 |
Total loss/gain on sale of assets | 2022-12-31 | $0 |
Total of all expenses incurred | 2022-12-31 | $102,282,999 |
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2022-12-31 | $101,252,401 |
Expenses. Certain deemed distributions of participant loans | 2022-12-31 | $14,983 |
Value of total corrective distributions | 2022-12-31 | $42,521 |
Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2022-12-31 | $180,119,186 |
Value of total assets at end of year | 2022-12-31 | $1,209,616,750 |
Value of total assets at beginning of year | 2022-12-31 | $1,367,389,311 |
Total of administrative expenses incurred including professional, contract, advisory and management fees | 2022-12-31 | $973,094 |
Total income from rents | 2022-12-31 | $0 |
Total interest from all sources | 2022-12-31 | $448,428 |
Total dividends received (eg from common stock, registered investment company shares) | 2022-12-31 | $38,700,399 |
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year | 2022-12-31 | No |
Total dividends received from registered investment company shares (eg mutual funds) | 2022-12-31 | $38,700,399 |
Assets. Real estate other than employer real property at end of year | 2022-12-31 | $0 |
Assets. Real estate other than employer real property at beginning of year | 2022-12-31 | $0 |
Administrative expenses professional fees incurred | 2022-12-31 | $0 |
Assets. Corporate prefeered stocks other than exployer securities at end of year | 2022-12-31 | $0 |
Assets. Corporate prefeered stocks other than exployer securities at beginning of year | 2022-12-31 | $0 |
Was this plan covered by a fidelity bond | 2022-12-31 | Yes |
Value of fidelity bond cover | 2022-12-31 | $10,000,000 |
If this is an individual account plan, was there a blackout period | 2022-12-31 | No |
Were there any nonexempt tranactions with any party-in-interest | 2022-12-31 | No |
Contributions received from participants | 2022-12-31 | $114,201,557 |
Participant contributions at end of year | 2022-12-31 | $10,281,993 |
Participant contributions at beginning of year | 2022-12-31 | $8,456,570 |
Participant contributions at end of year | 2022-12-31 | $0 |
Participant contributions at beginning of year | 2022-12-31 | $0 |
Assets. Other investments not covered elsewhere at end of year | 2022-12-31 | $0 |
Assets. Other investments not covered elsewhere at beginning of year | 2022-12-31 | $0 |
Income. Received or receivable in cash from other sources (including rollovers) | 2022-12-31 | $29,052,261 |
Expenses. Other payments made (not to insurance carriers or or participants/beneficiaries) | 2022-12-31 | $0 |
Value of other receiveables (less allowance for doubtful accounts) at end of year | 2022-12-31 | $0 |
Value of other receiveables (less allowance for doubtful accounts) at beginning of year | 2022-12-31 | $0 |
Assets. Loans (other than to participants) at end of year | 2022-12-31 | $0 |
Assets. Loans (other than to participants) at beginning of year | 2022-12-31 | $0 |
Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at end of year | 2022-12-31 | $0 |
Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at beginning of year | 2022-12-31 | $0 |
Other income not declared elsewhere | 2022-12-31 | $192,437 |
Administrative expenses (other) incurred | 2022-12-31 | $859,071 |
Liabilities. Value of operating payables at end of year | 2022-12-31 | $0 |
Liabilities. Value of operating payables at beginning of year | 2022-12-31 | $0 |
Total non interest bearing cash at end of year | 2022-12-31 | $0 |
Total non interest bearing cash at beginning of year | 2022-12-31 | $0 |
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser | 2022-12-31 | No |
Income. Non cash contributions | 2022-12-31 | $0 |
Value of net income/loss | 2022-12-31 | $-157,769,003 |
Value of net assets at end of year (total assets less liabilities) | 2022-12-31 | $1,209,616,750 |
Value of net assets at beginning of year (total assets less liabilities) | 2022-12-31 | $1,367,389,311 |
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond) | 2022-12-31 | No |
Were any loans by the plan or fixed income obligations due to the plan in default | 2022-12-31 | No |
Were any leases to which the plan was party in default or uncollectible | 2022-12-31 | No |
Assets. partnership/joint venture interests at end of year | 2022-12-31 | $0 |
Assets. partnership/joint venture interests at beginning of year | 2022-12-31 | $0 |
Investment advisory and management fees | 2022-12-31 | $114,023 |
Value of interest in registered invesment companies (eg mutual funds) at end of year | 2022-12-31 | $1,145,599,958 |
Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2022-12-31 | $1,315,135,131 |
Value of interest in pooled separate accounts at end of year | 2022-12-31 | $0 |
Value of interest in pooled separate accounts at beginning of year | 2022-12-31 | $0 |
Interest on participant loans | 2022-12-31 | $438,063 |
Income. Interest from loans (other than to participants) | 2022-12-31 | $0 |
Interest earned on other investments | 2022-12-31 | $0 |
Income. Interest from US Government securities | 2022-12-31 | $0 |
Income. Interest from corporate debt instruments | 2022-12-31 | $0 |
Value of interest in master investment trust accounts at end of year | 2022-12-31 | $0 |
Value of interest in master investment trust accounts at beginning of year | 2022-12-31 | $0 |
Value of interest in common/collective trusts at end of year | 2022-12-31 | $52,808,267 |
Value of interest in common/collective trusts at beginning of year | 2022-12-31 | $43,703,181 |
Value of interest bearing cash (including money market accounts and certificates of deposits) at end of year | 2022-12-31 | $926,532 |
Interest-bearing cash (include money market accounts & certificates of deposit) at beginning of the Year | 2022-12-31 | $94,429 |
Value of interest bearing cash (including money market accounts and certificates of deposits) at beginning of year | 2022-12-31 | $94,429 |
Interest earned from interest bearing cash (including money market accounts and certificates of deposit) | 2022-12-31 | $10,365 |
Assets. Value of investments in 103.12 investment entities at end of year | 2022-12-31 | $0 |
Assets. Value of investments in 103.12 investment entities at beginning of year | 2022-12-31 | $0 |
Value of funds held in insurance company general accounts (unallocated contracts) at end of year | 2022-12-31 | $0 |
Value of funds held in insurance company general accounts (unallocated contracts) at beginning of year | 2022-12-31 | $0 |
Expenses. Payments to insurance carriers foe the provision of benefits | 2022-12-31 | $0 |
Asset value of US Government securities at end of year | 2022-12-31 | $0 |
Asset value of US Government securities at beginning of year | 2022-12-31 | $0 |
Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2022-12-31 | $-275,905,951 |
Net investment gain/loss from pooled separate accounts | 2022-12-31 | $0 |
Net investment gain or loss from common/collective trusts | 2022-12-31 | $959,497 |
Net gain/loss from 103.12 investment entities | 2022-12-31 | $0 |
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets | 2022-12-31 | No |
Was there a failure to transmit to the plan any participant contributions | 2022-12-31 | Yes |
Has the plan failed to provide any benefit when due under the plan | 2022-12-31 | No |
Assets. Invements in employer securities at end of year | 2022-12-31 | $0 |
Assets. Invements in employer securities at beginning of year | 2022-12-31 | $0 |
Assets. Value of employer real property at end of year | 2022-12-31 | $0 |
Assets. Value of employer real property at beginning of year | 2022-12-31 | $0 |
Contributions received in cash from employer | 2022-12-31 | $36,865,368 |
Employer contributions (assets) at end of year | 2022-12-31 | $0 |
Employer contributions (assets) at beginning of year | 2022-12-31 | $0 |
Income. Dividends from preferred stock | 2022-12-31 | $0 |
Income. Dividends from common stock | 2022-12-31 | $0 |
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers | 2022-12-31 | $101,252,401 |
Asset. Corporate debt instrument preferred debt at end of year | 2022-12-31 | $0 |
Asset. Corporate debt instrument preferred debt at beginning of year | 2022-12-31 | $0 |
Asset. Corporate debt instrument debt (other) at end of year | 2022-12-31 | $0 |
Asset. Corporate debt instrument debt (other) at beginning of year | 2022-12-31 | $0 |
Contract administrator fees | 2022-12-31 | $0 |
Was the provided the required notice or one of the exceptions to providing the black out period notice applied under 29 CFR 2520.101-3 | 2022-12-31 | No |
Assets. Corporate common stocks other than exployer securities at end of year | 2022-12-31 | $0 |
Assets. Corporate common stocks other than exployer securities at beginning of year | 2022-12-31 | $0 |
Liabilities. Value of benefit claims payable at end of year | 2022-12-31 | $0 |
Liabilities. Value of benefit claims payable at beginning of year | 2022-12-31 | $0 |
Assets. Value of buildings and other operty used in plan operation at end of year | 2022-12-31 | $0 |
Assets. Value of buildings and other operty used in plan operation at beginning of year | 2022-12-31 | $0 |
Did the plan have assets held for investment | 2022-12-31 | Yes |
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser | 2022-12-31 | No |
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC | 2022-12-31 | No |
Aggregate proceeds on sale of assets | 2022-12-31 | $0 |
Aggregate carrying amount (costs) on sale of assets | 2022-12-31 | $0 |
Liabilities. Value of acquisition indebtedness at end of year | 2022-12-31 | $0 |
Liabilities. Value of acquisition indebtedness at beginning of year | 2022-12-31 | $0 |
Opinion of an independent qualified public accountant for this plan | 2022-12-31 | Unqualified |
Accountancy firm name | 2022-12-31 | PBMARES LLP |
Accountancy firm EIN | 2022-12-31 | 540737372 |
2021 : PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2021 401k financial data | ||
Unrealized appreciation/depreciation of real estate assets | 2021-12-31 | $0 |
Unrealized appreciation/depreciation of other (non real estate) assets | 2021-12-31 | $0 |
Total unrealized appreciation/depreciation of assets | 2021-12-31 | $0 |
Total transfer of assets to this plan | 2021-12-31 | $26,372,234 |
Total transfer of assets from this plan | 2021-12-31 | $0 |
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2021-12-31 | $0 |
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2021-12-31 | $0 |
Expenses. Interest paid | 2021-12-31 | $0 |
Amount of participant contributions which was failed to transmit to the plan within the time period described in 29 CFR 251.3-102 | 2021-12-31 | $0 |
Total income from all sources (including contributions) | 2021-12-31 | $335,581,816 |
Total loss/gain on sale of assets | 2021-12-31 | $0 |
Total of all expenses incurred | 2021-12-31 | $115,306,468 |
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2021-12-31 | $114,148,542 |
Expenses. Certain deemed distributions of participant loans | 2021-12-31 | $145,488 |
Value of total corrective distributions | 2021-12-31 | $2,680 |
Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2021-12-31 | $145,993,164 |
Value of total assets at end of year | 2021-12-31 | $1,367,389,311 |
Value of total assets at beginning of year | 2021-12-31 | $1,120,741,729 |
Total of administrative expenses incurred including professional, contract, advisory and management fees | 2021-12-31 | $1,009,758 |
Total income from rents | 2021-12-31 | $0 |
Total interest from all sources | 2021-12-31 | $409,674 |
Total dividends received (eg from common stock, registered investment company shares) | 2021-12-31 | $61,414,772 |
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year | 2021-12-31 | No |
Total dividends received from registered investment company shares (eg mutual funds) | 2021-12-31 | $61,414,772 |
Assets. Real estate other than employer real property at end of year | 2021-12-31 | $0 |
Assets. Real estate other than employer real property at beginning of year | 2021-12-31 | $0 |
Administrative expenses professional fees incurred | 2021-12-31 | $0 |
Assets. Corporate prefeered stocks other than exployer securities at end of year | 2021-12-31 | $0 |
Assets. Corporate prefeered stocks other than exployer securities at beginning of year | 2021-12-31 | $0 |
Was this plan covered by a fidelity bond | 2021-12-31 | Yes |
Value of fidelity bond cover | 2021-12-31 | $10,000,000 |
If this is an individual account plan, was there a blackout period | 2021-12-31 | Yes |
Were there any nonexempt tranactions with any party-in-interest | 2021-12-31 | No |
Contributions received from participants | 2021-12-31 | $87,267,964 |
Participant contributions at end of year | 2021-12-31 | $8,456,570 |
Participant contributions at beginning of year | 2021-12-31 | $7,064,603 |
Participant contributions at end of year | 2021-12-31 | $0 |
Participant contributions at beginning of year | 2021-12-31 | $0 |
Assets. Other investments not covered elsewhere at end of year | 2021-12-31 | $0 |
Assets. Other investments not covered elsewhere at beginning of year | 2021-12-31 | $0 |
Income. Received or receivable in cash from other sources (including rollovers) | 2021-12-31 | $33,304,057 |
Expenses. Other payments made (not to insurance carriers or or participants/beneficiaries) | 2021-12-31 | $0 |
Value of other receiveables (less allowance for doubtful accounts) at end of year | 2021-12-31 | $0 |
Value of other receiveables (less allowance for doubtful accounts) at beginning of year | 2021-12-31 | $0 |
Assets. Loans (other than to participants) at end of year | 2021-12-31 | $0 |
Assets. Loans (other than to participants) at beginning of year | 2021-12-31 | $0 |
Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at end of year | 2021-12-31 | $0 |
Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at beginning of year | 2021-12-31 | $0 |
Other income not declared elsewhere | 2021-12-31 | $205,174 |
Administrative expenses (other) incurred | 2021-12-31 | $989,428 |
Liabilities. Value of operating payables at end of year | 2021-12-31 | $0 |
Liabilities. Value of operating payables at beginning of year | 2021-12-31 | $0 |
Total non interest bearing cash at end of year | 2021-12-31 | $0 |
Total non interest bearing cash at beginning of year | 2021-12-31 | $0 |
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser | 2021-12-31 | No |
Income. Non cash contributions | 2021-12-31 | $0 |
Value of net income/loss | 2021-12-31 | $220,275,348 |
Value of net assets at end of year (total assets less liabilities) | 2021-12-31 | $1,367,389,311 |
Value of net assets at beginning of year (total assets less liabilities) | 2021-12-31 | $1,120,741,729 |
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond) | 2021-12-31 | No |
Were any loans by the plan or fixed income obligations due to the plan in default | 2021-12-31 | No |
Were any leases to which the plan was party in default or uncollectible | 2021-12-31 | No |
Assets. partnership/joint venture interests at end of year | 2021-12-31 | $0 |
Assets. partnership/joint venture interests at beginning of year | 2021-12-31 | $0 |
Investment advisory and management fees | 2021-12-31 | $20,330 |
Value of interest in registered invesment companies (eg mutual funds) at end of year | 2021-12-31 | $1,315,135,131 |
Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2021-12-31 | $1,068,071,425 |
Value of interest in pooled separate accounts at end of year | 2021-12-31 | $0 |
Value of interest in pooled separate accounts at beginning of year | 2021-12-31 | $0 |
Interest on participant loans | 2021-12-31 | $409,301 |
Income. Interest from loans (other than to participants) | 2021-12-31 | $0 |
Interest earned on other investments | 2021-12-31 | $0 |
Income. Interest from US Government securities | 2021-12-31 | $0 |
Income. Interest from corporate debt instruments | 2021-12-31 | $0 |
Value of interest in master investment trust accounts at end of year | 2021-12-31 | $0 |
Value of interest in master investment trust accounts at beginning of year | 2021-12-31 | $0 |
Value of interest in common/collective trusts at end of year | 2021-12-31 | $43,703,181 |
Value of interest in common/collective trusts at beginning of year | 2021-12-31 | $45,605,701 |
Value of interest bearing cash (including money market accounts and certificates of deposits) at end of year | 2021-12-31 | $94,429 |
Interest-bearing cash (include money market accounts & certificates of deposit) at beginning of the Year | 2021-12-31 | $0 |
Value of interest bearing cash (including money market accounts and certificates of deposits) at beginning of year | 2021-12-31 | $0 |
Interest earned from interest bearing cash (including money market accounts and certificates of deposit) | 2021-12-31 | $373 |
Assets. Value of investments in 103.12 investment entities at end of year | 2021-12-31 | $0 |
Assets. Value of investments in 103.12 investment entities at beginning of year | 2021-12-31 | $0 |
Value of funds held in insurance company general accounts (unallocated contracts) at end of year | 2021-12-31 | $0 |
Value of funds held in insurance company general accounts (unallocated contracts) at beginning of year | 2021-12-31 | $0 |
Expenses. Payments to insurance carriers foe the provision of benefits | 2021-12-31 | $0 |
Asset value of US Government securities at end of year | 2021-12-31 | $0 |
Asset value of US Government securities at beginning of year | 2021-12-31 | $0 |
Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2021-12-31 | $126,770,640 |
Net investment gain/loss from pooled separate accounts | 2021-12-31 | $0 |
Net investment gain or loss from common/collective trusts | 2021-12-31 | $788,392 |
Net gain/loss from 103.12 investment entities | 2021-12-31 | $0 |
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets | 2021-12-31 | No |
Was there a failure to transmit to the plan any participant contributions | 2021-12-31 | Yes |
Has the plan failed to provide any benefit when due under the plan | 2021-12-31 | No |
Assets. Invements in employer securities at end of year | 2021-12-31 | $0 |
Assets. Invements in employer securities at beginning of year | 2021-12-31 | $0 |
Assets. Value of employer real property at end of year | 2021-12-31 | $0 |
Assets. Value of employer real property at beginning of year | 2021-12-31 | $0 |
Contributions received in cash from employer | 2021-12-31 | $25,421,143 |
Employer contributions (assets) at end of year | 2021-12-31 | $0 |
Employer contributions (assets) at beginning of year | 2021-12-31 | $0 |
Income. Dividends from preferred stock | 2021-12-31 | $0 |
Income. Dividends from common stock | 2021-12-31 | $0 |
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers | 2021-12-31 | $114,148,542 |
Asset. Corporate debt instrument preferred debt at end of year | 2021-12-31 | $0 |
Asset. Corporate debt instrument preferred debt at beginning of year | 2021-12-31 | $0 |
Asset. Corporate debt instrument debt (other) at end of year | 2021-12-31 | $0 |
Asset. Corporate debt instrument debt (other) at beginning of year | 2021-12-31 | $0 |
Contract administrator fees | 2021-12-31 | $0 |
Was the provided the required notice or one of the exceptions to providing the black out period notice applied under 29 CFR 2520.101-3 | 2021-12-31 | Yes |
Assets. Corporate common stocks other than exployer securities at end of year | 2021-12-31 | $0 |
Assets. Corporate common stocks other than exployer securities at beginning of year | 2021-12-31 | $0 |
Liabilities. Value of benefit claims payable at end of year | 2021-12-31 | $0 |
Liabilities. Value of benefit claims payable at beginning of year | 2021-12-31 | $0 |
Assets. Value of buildings and other operty used in plan operation at end of year | 2021-12-31 | $0 |
Assets. Value of buildings and other operty used in plan operation at beginning of year | 2021-12-31 | $0 |
Did the plan have assets held for investment | 2021-12-31 | Yes |
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser | 2021-12-31 | No |
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC | 2021-12-31 | No |
Aggregate proceeds on sale of assets | 2021-12-31 | $0 |
Aggregate carrying amount (costs) on sale of assets | 2021-12-31 | $0 |
Liabilities. Value of acquisition indebtedness at end of year | 2021-12-31 | $0 |
Liabilities. Value of acquisition indebtedness at beginning of year | 2021-12-31 | $0 |
Opinion of an independent qualified public accountant for this plan | 2021-12-31 | Unqualified |
Accountancy firm name | 2021-12-31 | PBMARES LLP |
Accountancy firm EIN | 2021-12-31 | 540737372 |
2020 : PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2020 401k financial data | ||
Total unrealized appreciation/depreciation of assets | 2020-12-31 | $0 |
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2020-12-31 | $0 |
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2020-12-31 | $0 |
Total income from all sources (including contributions) | 2020-12-31 | $263,394,273 |
Total loss/gain on sale of assets | 2020-12-31 | $0 |
Total of all expenses incurred | 2020-12-31 | $66,155,837 |
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2020-12-31 | $65,197,623 |
Expenses. Certain deemed distributions of participant loans | 2020-12-31 | $68,356 |
Value of total corrective distributions | 2020-12-31 | $13,040 |
Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2020-12-31 | $106,542,942 |
Value of total assets at end of year | 2020-12-31 | $1,120,741,729 |
Value of total assets at beginning of year | 2020-12-31 | $923,503,293 |
Total of administrative expenses incurred including professional, contract, advisory and management fees | 2020-12-31 | $876,818 |
Total interest from all sources | 2020-12-31 | $382,602 |
Total dividends received (eg from common stock, registered investment company shares) | 2020-12-31 | $34,271,347 |
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year | 2020-12-31 | No |
Total dividends received from registered investment company shares (eg mutual funds) | 2020-12-31 | $34,271,347 |
Administrative expenses professional fees incurred | 2020-12-31 | $17,500 |
Was this plan covered by a fidelity bond | 2020-12-31 | Yes |
Value of fidelity bond cover | 2020-12-31 | $10,000,000 |
If this is an individual account plan, was there a blackout period | 2020-12-31 | No |
Were there any nonexempt tranactions with any party-in-interest | 2020-12-31 | No |
Contributions received from participants | 2020-12-31 | $70,106,250 |
Participant contributions at end of year | 2020-12-31 | $7,064,603 |
Participant contributions at beginning of year | 2020-12-31 | $6,919,014 |
Income. Received or receivable in cash from other sources (including rollovers) | 2020-12-31 | $15,638,270 |
Other income not declared elsewhere | 2020-12-31 | $822,053 |
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser | 2020-12-31 | No |
Value of net income/loss | 2020-12-31 | $197,238,436 |
Value of net assets at end of year (total assets less liabilities) | 2020-12-31 | $1,120,741,729 |
Value of net assets at beginning of year (total assets less liabilities) | 2020-12-31 | $923,503,293 |
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond) | 2020-12-31 | No |
Were any loans by the plan or fixed income obligations due to the plan in default | 2020-12-31 | No |
Were any leases to which the plan was party in default or uncollectible | 2020-12-31 | No |
Investment advisory and management fees | 2020-12-31 | $119,076 |
Value of interest in registered invesment companies (eg mutual funds) at end of year | 2020-12-31 | $1,068,071,425 |
Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2020-12-31 | $879,717,042 |
Interest on participant loans | 2020-12-31 | $382,602 |
Value of interest in common/collective trusts at end of year | 2020-12-31 | $45,605,701 |
Value of interest in common/collective trusts at beginning of year | 2020-12-31 | $36,867,237 |
Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2020-12-31 | $120,487,344 |
Net investment gain or loss from common/collective trusts | 2020-12-31 | $887,985 |
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets | 2020-12-31 | No |
Was there a failure to transmit to the plan any participant contributions | 2020-12-31 | No |
Has the plan failed to provide any benefit when due under the plan | 2020-12-31 | No |
Contributions received in cash from employer | 2020-12-31 | $20,798,422 |
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers | 2020-12-31 | $65,197,623 |
Contract administrator fees | 2020-12-31 | $740,242 |
Did the plan have assets held for investment | 2020-12-31 | Yes |
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser | 2020-12-31 | No |
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC | 2020-12-31 | No |
Opinion of an independent qualified public accountant for this plan | 2020-12-31 | Disclaimer |
Accountancy firm name | 2020-12-31 | PBMARES LLP |
Accountancy firm EIN | 2020-12-31 | 540737372 |
2019 : PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2019 401k financial data | ||
Total unrealized appreciation/depreciation of assets | 2019-12-31 | $0 |
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2019-12-31 | $0 |
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2019-12-31 | $0 |
Total income from all sources (including contributions) | 2019-12-31 | $271,650,873 |
Total loss/gain on sale of assets | 2019-12-31 | $0 |
Total of all expenses incurred | 2019-12-31 | $69,754,454 |
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2019-12-31 | $68,911,066 |
Expenses. Certain deemed distributions of participant loans | 2019-12-31 | $54,807 |
Value of total corrective distributions | 2019-12-31 | $24,860 |
Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2019-12-31 | $92,941,231 |
Value of total assets at end of year | 2019-12-31 | $923,503,293 |
Value of total assets at beginning of year | 2019-12-31 | $721,606,874 |
Total of administrative expenses incurred including professional, contract, advisory and management fees | 2019-12-31 | $763,721 |
Total interest from all sources | 2019-12-31 | $365,947 |
Total dividends received (eg from common stock, registered investment company shares) | 2019-12-31 | $35,021,700 |
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year | 2019-12-31 | No |
Total dividends received from registered investment company shares (eg mutual funds) | 2019-12-31 | $35,021,700 |
Administrative expenses professional fees incurred | 2019-12-31 | $19,120 |
Was this plan covered by a fidelity bond | 2019-12-31 | Yes |
Value of fidelity bond cover | 2019-12-31 | $10,000,000 |
If this is an individual account plan, was there a blackout period | 2019-12-31 | No |
Were there any nonexempt tranactions with any party-in-interest | 2019-12-31 | No |
Contributions received from participants | 2019-12-31 | $59,146,671 |
Participant contributions at end of year | 2019-12-31 | $6,919,014 |
Participant contributions at beginning of year | 2019-12-31 | $6,738,715 |
Income. Received or receivable in cash from other sources (including rollovers) | 2019-12-31 | $15,989,863 |
Other income not declared elsewhere | 2019-12-31 | $663,867 |
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser | 2019-12-31 | No |
Value of net income/loss | 2019-12-31 | $201,896,419 |
Value of net assets at end of year (total assets less liabilities) | 2019-12-31 | $923,503,293 |
Value of net assets at beginning of year (total assets less liabilities) | 2019-12-31 | $721,606,874 |
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond) | 2019-12-31 | No |
Were any loans by the plan or fixed income obligations due to the plan in default | 2019-12-31 | No |
Were any leases to which the plan was party in default or uncollectible | 2019-12-31 | No |
Investment advisory and management fees | 2019-12-31 | $69,556 |
Value of interest in registered invesment companies (eg mutual funds) at end of year | 2019-12-31 | $879,717,042 |
Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2019-12-31 | $679,543,186 |
Interest on participant loans | 2019-12-31 | $365,947 |
Value of interest in common/collective trusts at end of year | 2019-12-31 | $36,867,237 |
Value of interest in common/collective trusts at beginning of year | 2019-12-31 | $35,324,973 |
Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2019-12-31 | $141,853,579 |
Net investment gain or loss from common/collective trusts | 2019-12-31 | $804,549 |
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets | 2019-12-31 | No |
Was there a failure to transmit to the plan any participant contributions | 2019-12-31 | No |
Has the plan failed to provide any benefit when due under the plan | 2019-12-31 | No |
Contributions received in cash from employer | 2019-12-31 | $17,804,697 |
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers | 2019-12-31 | $68,911,066 |
Contract administrator fees | 2019-12-31 | $675,045 |
Did the plan have assets held for investment | 2019-12-31 | Yes |
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser | 2019-12-31 | No |
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC | 2019-12-31 | No |
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d) | 2019-12-31 | Yes |
Opinion of an independent qualified public accountant for this plan | 2019-12-31 | Disclaimer |
Accountancy firm name | 2019-12-31 | RSM US LLP |
Accountancy firm EIN | 2019-12-31 | 420714325 |
2018 : PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2018 401k financial data | ||
Total unrealized appreciation/depreciation of assets | 2018-12-31 | $0 |
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2018-12-31 | $0 |
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2018-12-31 | $0 |
Total income from all sources (including contributions) | 2018-12-31 | $32,284,867 |
Total loss/gain on sale of assets | 2018-12-31 | $0 |
Total of all expenses incurred | 2018-12-31 | $56,254,482 |
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2018-12-31 | $55,387,664 |
Expenses. Certain deemed distributions of participant loans | 2018-12-31 | $115,183 |
Value of total corrective distributions | 2018-12-31 | $15,963 |
Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2018-12-31 | $80,258,852 |
Value of total assets at end of year | 2018-12-31 | $721,606,874 |
Value of total assets at beginning of year | 2018-12-31 | $745,576,489 |
Total of administrative expenses incurred including professional, contract, advisory and management fees | 2018-12-31 | $735,672 |
Total interest from all sources | 2018-12-31 | $318,598 |
Total dividends received (eg from common stock, registered investment company shares) | 2018-12-31 | $38,984,449 |
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year | 2018-12-31 | No |
Total dividends received from registered investment company shares (eg mutual funds) | 2018-12-31 | $38,984,449 |
Administrative expenses professional fees incurred | 2018-12-31 | $22,705 |
Was this plan covered by a fidelity bond | 2018-12-31 | Yes |
Value of fidelity bond cover | 2018-12-31 | $10,000,000 |
If this is an individual account plan, was there a blackout period | 2018-12-31 | No |
Were there any nonexempt tranactions with any party-in-interest | 2018-12-31 | No |
Contributions received from participants | 2018-12-31 | $53,687,136 |
Participant contributions at end of year | 2018-12-31 | $6,738,715 |
Participant contributions at beginning of year | 2018-12-31 | $6,610,286 |
Income. Received or receivable in cash from other sources (including rollovers) | 2018-12-31 | $10,542,105 |
Other income not declared elsewhere | 2018-12-31 | $716,296 |
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser | 2018-12-31 | No |
Value of net income/loss | 2018-12-31 | $-23,969,615 |
Value of net assets at end of year (total assets less liabilities) | 2018-12-31 | $721,606,874 |
Value of net assets at beginning of year (total assets less liabilities) | 2018-12-31 | $745,576,489 |
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond) | 2018-12-31 | No |
Were any loans by the plan or fixed income obligations due to the plan in default | 2018-12-31 | No |
Were any leases to which the plan was party in default or uncollectible | 2018-12-31 | No |
Investment advisory and management fees | 2018-12-31 | $90,378 |
Value of interest in registered invesment companies (eg mutual funds) at end of year | 2018-12-31 | $679,543,186 |
Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2018-12-31 | $707,837,353 |
Interest on participant loans | 2018-12-31 | $318,598 |
Value of interest in common/collective trusts at end of year | 2018-12-31 | $35,324,973 |
Value of interest in common/collective trusts at beginning of year | 2018-12-31 | $31,128,850 |
Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2018-12-31 | $-88,639,898 |
Net investment gain or loss from common/collective trusts | 2018-12-31 | $646,570 |
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets | 2018-12-31 | No |
Was there a failure to transmit to the plan any participant contributions | 2018-12-31 | No |
Has the plan failed to provide any benefit when due under the plan | 2018-12-31 | No |
Contributions received in cash from employer | 2018-12-31 | $16,029,611 |
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers | 2018-12-31 | $55,387,664 |
Contract administrator fees | 2018-12-31 | $622,589 |
Did the plan have assets held for investment | 2018-12-31 | Yes |
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser | 2018-12-31 | No |
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC | 2018-12-31 | No |
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d) | 2018-12-31 | Yes |
Opinion of an independent qualified public accountant for this plan | 2018-12-31 | Disclaimer |
Accountancy firm name | 2018-12-31 | RSM US LLP |
Accountancy firm EIN | 2018-12-31 | 420714325 |
2017 : PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2017 401k financial data | ||
Total unrealized appreciation/depreciation of assets | 2017-12-31 | $0 |
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2017-12-31 | $0 |
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2017-12-31 | $0 |
Total income from all sources (including contributions) | 2017-12-31 | $186,445,891 |
Total loss/gain on sale of assets | 2017-12-31 | $0 |
Total of all expenses incurred | 2017-12-31 | $50,395,981 |
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2017-12-31 | $50,036,371 |
Expenses. Certain deemed distributions of participant loans | 2017-12-31 | $8,359 |
Value of total corrective distributions | 2017-12-31 | $11,768 |
Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2017-12-31 | $76,883,107 |
Value of total assets at end of year | 2017-12-31 | $745,576,489 |
Value of total assets at beginning of year | 2017-12-31 | $609,526,579 |
Total of administrative expenses incurred including professional, contract, advisory and management fees | 2017-12-31 | $339,483 |
Total interest from all sources | 2017-12-31 | $278,831 |
Total dividends received (eg from common stock, registered investment company shares) | 2017-12-31 | $29,262,325 |
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year | 2017-12-31 | No |
Total dividends received from registered investment company shares (eg mutual funds) | 2017-12-31 | $29,262,325 |
Administrative expenses professional fees incurred | 2017-12-31 | $35,184 |
Was this plan covered by a fidelity bond | 2017-12-31 | Yes |
Value of fidelity bond cover | 2017-12-31 | $10,000,000 |
If this is an individual account plan, was there a blackout period | 2017-12-31 | No |
Were there any nonexempt tranactions with any party-in-interest | 2017-12-31 | No |
Contributions received from participants | 2017-12-31 | $50,432,072 |
Participant contributions at end of year | 2017-12-31 | $6,610,286 |
Participant contributions at beginning of year | 2017-12-31 | $6,080,162 |
Income. Received or receivable in cash from other sources (including rollovers) | 2017-12-31 | $11,135,892 |
Value of other receiveables (less allowance for doubtful accounts) at beginning of year | 2017-12-31 | $2,399,980 |
Other income not declared elsewhere | 2017-12-31 | $258,290 |
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser | 2017-12-31 | No |
Value of net income/loss | 2017-12-31 | $136,049,910 |
Value of net assets at end of year (total assets less liabilities) | 2017-12-31 | $745,576,489 |
Value of net assets at beginning of year (total assets less liabilities) | 2017-12-31 | $609,526,579 |
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond) | 2017-12-31 | No |
Were any loans by the plan or fixed income obligations due to the plan in default | 2017-12-31 | No |
Were any leases to which the plan was party in default or uncollectible | 2017-12-31 | No |
Investment advisory and management fees | 2017-12-31 | $109,283 |
Value of interest in registered invesment companies (eg mutual funds) at end of year | 2017-12-31 | $707,837,353 |
Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2017-12-31 | $569,116,398 |
Interest on participant loans | 2017-12-31 | $278,831 |
Value of interest in common/collective trusts at end of year | 2017-12-31 | $31,128,850 |
Value of interest in common/collective trusts at beginning of year | 2017-12-31 | $31,930,039 |
Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2017-12-31 | $79,230,617 |
Net investment gain or loss from common/collective trusts | 2017-12-31 | $532,721 |
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets | 2017-12-31 | No |
Was there a failure to transmit to the plan any participant contributions | 2017-12-31 | No |
Has the plan failed to provide any benefit when due under the plan | 2017-12-31 | No |
Contributions received in cash from employer | 2017-12-31 | $15,315,143 |
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers | 2017-12-31 | $50,036,371 |
Contract administrator fees | 2017-12-31 | $195,016 |
Did the plan have assets held for investment | 2017-12-31 | Yes |
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser | 2017-12-31 | No |
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC | 2017-12-31 | No |
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d) | 2017-12-31 | Yes |
Opinion of an independent qualified public accountant for this plan | 2017-12-31 | Disclaimer |
Accountancy firm name | 2017-12-31 | RSM US LLP |
Accountancy firm EIN | 2017-12-31 | 420714325 |
2016 : PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2016 401k financial data | ||
Total unrealized appreciation/depreciation of assets | 2016-12-31 | $0 |
Total transfer of assets to this plan | 2016-12-31 | $2,399,980 |
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2016-12-31 | $0 |
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2016-12-31 | $0 |
Total income from all sources (including contributions) | 2016-12-31 | $121,014,575 |
Total loss/gain on sale of assets | 2016-12-31 | $0 |
Total of all expenses incurred | 2016-12-31 | $39,995,133 |
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2016-12-31 | $39,698,318 |
Expenses. Certain deemed distributions of participant loans | 2016-12-31 | $132,287 |
Value of total corrective distributions | 2016-12-31 | $10,308 |
Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2016-12-31 | $71,583,790 |
Value of total assets at end of year | 2016-12-31 | $609,526,579 |
Value of total assets at beginning of year | 2016-12-31 | $526,107,157 |
Total of administrative expenses incurred including professional, contract, advisory and management fees | 2016-12-31 | $154,220 |
Total interest from all sources | 2016-12-31 | $237,927 |
Total dividends received (eg from common stock, registered investment company shares) | 2016-12-31 | $16,952,346 |
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year | 2016-12-31 | No |
Total dividends received from registered investment company shares (eg mutual funds) | 2016-12-31 | $16,952,346 |
Administrative expenses professional fees incurred | 2016-12-31 | $154,220 |
Was this plan covered by a fidelity bond | 2016-12-31 | Yes |
Value of fidelity bond cover | 2016-12-31 | $10,000,000 |
If this is an individual account plan, was there a blackout period | 2016-12-31 | No |
Were there any nonexempt tranactions with any party-in-interest | 2016-12-31 | No |
Contributions received from participants | 2016-12-31 | $45,198,156 |
Participant contributions at end of year | 2016-12-31 | $6,080,162 |
Participant contributions at beginning of year | 2016-12-31 | $5,550,908 |
Income. Received or receivable in cash from other sources (including rollovers) | 2016-12-31 | $12,664,490 |
Value of other receiveables (less allowance for doubtful accounts) at end of year | 2016-12-31 | $2,399,980 |
Other income not declared elsewhere | 2016-12-31 | $269,742 |
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser | 2016-12-31 | No |
Value of net income/loss | 2016-12-31 | $81,019,442 |
Value of net assets at end of year (total assets less liabilities) | 2016-12-31 | $609,526,579 |
Value of net assets at beginning of year (total assets less liabilities) | 2016-12-31 | $526,107,157 |
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond) | 2016-12-31 | No |
Were any loans by the plan or fixed income obligations due to the plan in default | 2016-12-31 | No |
Were any leases to which the plan was party in default or uncollectible | 2016-12-31 | No |
Value of interest in registered invesment companies (eg mutual funds) at end of year | 2016-12-31 | $569,116,398 |
Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2016-12-31 | $491,598,400 |
Interest on participant loans | 2016-12-31 | $237,927 |
Value of interest in common/collective trusts at end of year | 2016-12-31 | $31,930,039 |
Value of interest in common/collective trusts at beginning of year | 2016-12-31 | $28,957,849 |
Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2016-12-31 | $31,502,067 |
Net investment gain or loss from common/collective trusts | 2016-12-31 | $468,703 |
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets | 2016-12-31 | No |
Was there a failure to transmit to the plan any participant contributions | 2016-12-31 | No |
Has the plan failed to provide any benefit when due under the plan | 2016-12-31 | No |
Contributions received in cash from employer | 2016-12-31 | $13,721,144 |
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers | 2016-12-31 | $39,698,318 |
Did the plan have assets held for investment | 2016-12-31 | Yes |
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser | 2016-12-31 | No |
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC | 2016-12-31 | No |
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d) | 2016-12-31 | Yes |
Opinion of an independent qualified public accountant for this plan | 2016-12-31 | Disclaimer |
Accountancy firm name | 2016-12-31 | RSM US LLP |
Accountancy firm EIN | 2016-12-31 | 420714325 |
2015 : PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2015 401k financial data | ||
Total unrealized appreciation/depreciation of assets | 2015-12-31 | $0 |
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2015-12-31 | $0 |
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2015-12-31 | $0 |
Total income from all sources (including contributions) | 2015-12-31 | $61,018,159 |
Total loss/gain on sale of assets | 2015-12-31 | $0 |
Total of all expenses incurred | 2015-12-31 | $36,095,912 |
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2015-12-31 | $35,784,209 |
Expenses. Certain deemed distributions of participant loans | 2015-12-31 | $187,388 |
Value of total corrective distributions | 2015-12-31 | $3,162 |
Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2015-12-31 | $62,834,182 |
Value of total assets at end of year | 2015-12-31 | $526,107,157 |
Value of total assets at beginning of year | 2015-12-31 | $501,184,910 |
Total of administrative expenses incurred including professional, contract, advisory and management fees | 2015-12-31 | $121,153 |
Total interest from all sources | 2015-12-31 | $214,774 |
Total dividends received (eg from common stock, registered investment company shares) | 2015-12-31 | $24,867,302 |
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year | 2015-12-31 | No |
Total dividends received from registered investment company shares (eg mutual funds) | 2015-12-31 | $24,867,302 |
Administrative expenses professional fees incurred | 2015-12-31 | $121,153 |
Was this plan covered by a fidelity bond | 2015-12-31 | Yes |
Value of fidelity bond cover | 2015-12-31 | $10,000,000 |
If this is an individual account plan, was there a blackout period | 2015-12-31 | No |
Were there any nonexempt tranactions with any party-in-interest | 2015-12-31 | No |
Contributions received from participants | 2015-12-31 | $40,504,472 |
Participant contributions at end of year | 2015-12-31 | $5,550,908 |
Participant contributions at beginning of year | 2015-12-31 | $4,750,205 |
Participant contributions at beginning of year | 2015-12-31 | $105 |
Income. Received or receivable in cash from other sources (including rollovers) | 2015-12-31 | $9,968,017 |
Other income not declared elsewhere | 2015-12-31 | $115,283 |
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser | 2015-12-31 | No |
Value of net income/loss | 2015-12-31 | $24,922,247 |
Value of net assets at end of year (total assets less liabilities) | 2015-12-31 | $526,107,157 |
Value of net assets at beginning of year (total assets less liabilities) | 2015-12-31 | $501,184,910 |
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond) | 2015-12-31 | No |
Were any loans by the plan or fixed income obligations due to the plan in default | 2015-12-31 | No |
Were any leases to which the plan was party in default or uncollectible | 2015-12-31 | No |
Value of interest in registered invesment companies (eg mutual funds) at end of year | 2015-12-31 | $491,598,400 |
Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2015-12-31 | $469,711,929 |
Interest on participant loans | 2015-12-31 | $214,774 |
Value of interest in common/collective trusts at end of year | 2015-12-31 | $28,957,849 |
Value of interest in common/collective trusts at beginning of year | 2015-12-31 | $26,722,403 |
Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2015-12-31 | $-27,398,536 |
Net investment gain or loss from common/collective trusts | 2015-12-31 | $385,154 |
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets | 2015-12-31 | No |
Was there a failure to transmit to the plan any participant contributions | 2015-12-31 | No |
Has the plan failed to provide any benefit when due under the plan | 2015-12-31 | No |
Contributions received in cash from employer | 2015-12-31 | $12,361,693 |
Employer contributions (assets) at beginning of year | 2015-12-31 | $268 |
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers | 2015-12-31 | $35,784,209 |
Did the plan have assets held for investment | 2015-12-31 | Yes |
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser | 2015-12-31 | No |
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC | 2015-12-31 | No |
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d) | 2015-12-31 | Yes |
Opinion of an independent qualified public accountant for this plan | 2015-12-31 | Disclaimer |
Accountancy firm name | 2015-12-31 | RSM US LLP |
Accountancy firm EIN | 2015-12-31 | 420714325 |
2014 : PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2014 401k financial data | ||
Total unrealized appreciation/depreciation of assets | 2014-12-31 | $0 |
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2014-12-31 | $0 |
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2014-12-31 | $0 |
Total income from all sources (including contributions) | 2014-12-31 | $82,993,943 |
Total loss/gain on sale of assets | 2014-12-31 | $0 |
Total of all expenses incurred | 2014-12-31 | $37,294,190 |
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2014-12-31 | $37,131,226 |
Expenses. Certain deemed distributions of participant loans | 2014-12-31 | $27,646 |
Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2014-12-31 | $52,153,003 |
Value of total assets at end of year | 2014-12-31 | $501,184,910 |
Value of total assets at beginning of year | 2014-12-31 | $455,485,157 |
Total of administrative expenses incurred including professional, contract, advisory and management fees | 2014-12-31 | $135,318 |
Total interest from all sources | 2014-12-31 | $193,730 |
Total dividends received (eg from common stock, registered investment company shares) | 2014-12-31 | $27,017,408 |
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year | 2014-12-31 | No |
Total dividends received from registered investment company shares (eg mutual funds) | 2014-12-31 | $27,017,408 |
Was this plan covered by a fidelity bond | 2014-12-31 | Yes |
Value of fidelity bond cover | 2014-12-31 | $10,000,000 |
If this is an individual account plan, was there a blackout period | 2014-12-31 | No |
Were there any nonexempt tranactions with any party-in-interest | 2014-12-31 | No |
Contributions received from participants | 2014-12-31 | $35,548,473 |
Participant contributions at end of year | 2014-12-31 | $4,750,205 |
Participant contributions at beginning of year | 2014-12-31 | $4,598,473 |
Participant contributions at end of year | 2014-12-31 | $105 |
Participant contributions at beginning of year | 2014-12-31 | $2,690 |
Income. Received or receivable in cash from other sources (including rollovers) | 2014-12-31 | $5,599,745 |
Other income not declared elsewhere | 2014-12-31 | $97,465 |
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser | 2014-12-31 | No |
Value of net income/loss | 2014-12-31 | $45,699,753 |
Value of net assets at end of year (total assets less liabilities) | 2014-12-31 | $501,184,910 |
Value of net assets at beginning of year (total assets less liabilities) | 2014-12-31 | $455,485,157 |
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond) | 2014-12-31 | No |
Were any loans by the plan or fixed income obligations due to the plan in default | 2014-12-31 | No |
Were any leases to which the plan was party in default or uncollectible | 2014-12-31 | No |
Investment advisory and management fees | 2014-12-31 | $81,680 |
Value of interest in registered invesment companies (eg mutual funds) at end of year | 2014-12-31 | $469,711,929 |
Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2014-12-31 | $424,218,839 |
Interest on participant loans | 2014-12-31 | $193,730 |
Value of interest in common/collective trusts at end of year | 2014-12-31 | $26,722,403 |
Value of interest in common/collective trusts at beginning of year | 2014-12-31 | $26,664,031 |
Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2014-12-31 | $3,266,817 |
Net investment gain or loss from common/collective trusts | 2014-12-31 | $265,520 |
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets | 2014-12-31 | No |
Was there a failure to transmit to the plan any participant contributions | 2014-12-31 | No |
Has the plan failed to provide any benefit when due under the plan | 2014-12-31 | No |
Contributions received in cash from employer | 2014-12-31 | $11,004,785 |
Employer contributions (assets) at end of year | 2014-12-31 | $268 |
Employer contributions (assets) at beginning of year | 2014-12-31 | $1,124 |
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers | 2014-12-31 | $37,131,226 |
Contract administrator fees | 2014-12-31 | $53,638 |
Did the plan have assets held for investment | 2014-12-31 | Yes |
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser | 2014-12-31 | No |
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC | 2014-12-31 | No |
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d) | 2014-12-31 | Yes |
Opinion of an independent qualified public accountant for this plan | 2014-12-31 | Disclaimer |
Accountancy firm name | 2014-12-31 | MCGLADREY LLP |
Accountancy firm EIN | 2014-12-31 | 420714325 |
2013 : PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2013 401k financial data | ||
Total unrealized appreciation/depreciation of assets | 2013-12-31 | $0 |
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2013-12-31 | $0 |
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2013-12-31 | $0 |
Total income from all sources (including contributions) | 2013-12-31 | $126,525,998 |
Total loss/gain on sale of assets | 2013-12-31 | $0 |
Total of all expenses incurred | 2013-12-31 | $22,450,357 |
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2013-12-31 | $22,398,182 |
Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2013-12-31 | $47,966,024 |
Value of total assets at end of year | 2013-12-31 | $455,485,157 |
Value of total assets at beginning of year | 2013-12-31 | $351,409,516 |
Total of administrative expenses incurred including professional, contract, advisory and management fees | 2013-12-31 | $52,175 |
Total interest from all sources | 2013-12-31 | $175,886 |
Total dividends received (eg from common stock, registered investment company shares) | 2013-12-31 | $16,119,499 |
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year | 2013-12-31 | No |
Total dividends received from registered investment company shares (eg mutual funds) | 2013-12-31 | $16,119,499 |
Was this plan covered by a fidelity bond | 2013-12-31 | Yes |
Value of fidelity bond cover | 2013-12-31 | $10,000,000 |
If this is an individual account plan, was there a blackout period | 2013-12-31 | No |
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities | 2013-12-31 | $0 |
Were there any nonexempt tranactions with any party-in-interest | 2013-12-31 | No |
Contributions received from participants | 2013-12-31 | $33,334,730 |
Participant contributions at end of year | 2013-12-31 | $4,598,473 |
Participant contributions at beginning of year | 2013-12-31 | $4,205,996 |
Participant contributions at end of year | 2013-12-31 | $2,690 |
Participant contributions at beginning of year | 2013-12-31 | $1,547 |
Income. Received or receivable in cash from other sources (including rollovers) | 2013-12-31 | $4,325,952 |
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser | 2013-12-31 | No |
Value of net income/loss | 2013-12-31 | $104,075,641 |
Value of net assets at end of year (total assets less liabilities) | 2013-12-31 | $455,485,157 |
Value of net assets at beginning of year (total assets less liabilities) | 2013-12-31 | $351,409,516 |
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond) | 2013-12-31 | No |
Were any loans by the plan or fixed income obligations due to the plan in default | 2013-12-31 | No |
Were any leases to which the plan was party in default or uncollectible | 2013-12-31 | No |
Value of interest in registered invesment companies (eg mutual funds) at end of year | 2013-12-31 | $424,218,839 |
Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2013-12-31 | $321,885,699 |
Interest on participant loans | 2013-12-31 | $175,886 |
Value of interest in common/collective trusts at end of year | 2013-12-31 | $26,664,031 |
Value of interest in common/collective trusts at beginning of year | 2013-12-31 | $25,315,681 |
Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2013-12-31 | $62,081,711 |
Net investment gain or loss from common/collective trusts | 2013-12-31 | $182,878 |
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets | 2013-12-31 | No |
Was there a failure to transmit to the plan any participant contributions | 2013-12-31 | No |
Has the plan failed to provide any benefit when due under the plan | 2013-12-31 | No |
Contributions received in cash from employer | 2013-12-31 | $10,305,342 |
Employer contributions (assets) at end of year | 2013-12-31 | $1,124 |
Employer contributions (assets) at beginning of year | 2013-12-31 | $593 |
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers | 2013-12-31 | $22,398,182 |
Contract administrator fees | 2013-12-31 | $52,175 |
Was the provided the required notice or one of the exceptions to providing the black out period notice applied under 29 CFR 2520.101-3 | 2013-12-31 | No |
Did the plan have assets held for investment | 2013-12-31 | Yes |
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser | 2013-12-31 | No |
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC | 2013-12-31 | No |
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d) | 2013-12-31 | Yes |
Opinion of an independent qualified public accountant for this plan | 2013-12-31 | Disclaimer |
Accountancy firm name | 2013-12-31 | MCGLADREY LLP |
Accountancy firm EIN | 2013-12-31 | 420714325 |
2012 : PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2012 401k financial data | ||
Total unrealized appreciation/depreciation of assets | 2012-12-31 | $0 |
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2012-12-31 | $0 |
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2012-12-31 | $0 |
Total income from all sources (including contributions) | 2012-12-31 | $81,854,705 |
Total loss/gain on sale of assets | 2012-12-31 | $0 |
Total of all expenses incurred | 2012-12-31 | $25,713,558 |
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2012-12-31 | $25,658,982 |
Expenses. Certain deemed distributions of participant loans | 2012-12-31 | $5,988 |
Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2012-12-31 | $41,516,288 |
Value of total assets at end of year | 2012-12-31 | $351,409,516 |
Value of total assets at beginning of year | 2012-12-31 | $295,268,369 |
Total of administrative expenses incurred including professional, contract, advisory and management fees | 2012-12-31 | $48,588 |
Total interest from all sources | 2012-12-31 | $166,527 |
Total dividends received (eg from common stock, registered investment company shares) | 2012-12-31 | $9,075,679 |
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year | 2012-12-31 | No |
Total dividends received from registered investment company shares (eg mutual funds) | 2012-12-31 | $9,075,679 |
Was this plan covered by a fidelity bond | 2012-12-31 | Yes |
Value of fidelity bond cover | 2012-12-31 | $10,000,000 |
If this is an individual account plan, was there a blackout period | 2012-12-31 | No |
Were there any nonexempt tranactions with any party-in-interest | 2012-12-31 | No |
Contributions received from participants | 2012-12-31 | $29,427,173 |
Participant contributions at end of year | 2012-12-31 | $4,205,996 |
Participant contributions at beginning of year | 2012-12-31 | $3,719,099 |
Participant contributions at end of year | 2012-12-31 | $1,547 |
Participant contributions at beginning of year | 2012-12-31 | $1,456 |
Income. Received or receivable in cash from other sources (including rollovers) | 2012-12-31 | $2,744,007 |
Value of other receiveables (less allowance for doubtful accounts) at beginning of year | 2012-12-31 | $0 |
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser | 2012-12-31 | No |
Value of net income/loss | 2012-12-31 | $56,141,147 |
Value of net assets at end of year (total assets less liabilities) | 2012-12-31 | $351,409,516 |
Value of net assets at beginning of year (total assets less liabilities) | 2012-12-31 | $295,268,369 |
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond) | 2012-12-31 | No |
Were any loans by the plan or fixed income obligations due to the plan in default | 2012-12-31 | No |
Were any leases to which the plan was party in default or uncollectible | 2012-12-31 | No |
Value of interest in registered invesment companies (eg mutual funds) at end of year | 2012-12-31 | $321,885,699 |
Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2012-12-31 | $267,575,759 |
Interest on participant loans | 2012-12-31 | $166,527 |
Value of interest in common/collective trusts at end of year | 2012-12-31 | $25,315,681 |
Value of interest in common/collective trusts at beginning of year | 2012-12-31 | $23,971,865 |
Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2012-12-31 | $30,835,882 |
Net investment gain or loss from common/collective trusts | 2012-12-31 | $260,329 |
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets | 2012-12-31 | No |
Was there a failure to transmit to the plan any participant contributions | 2012-12-31 | No |
Has the plan failed to provide any benefit when due under the plan | 2012-12-31 | No |
Contributions received in cash from employer | 2012-12-31 | $9,345,108 |
Employer contributions (assets) at end of year | 2012-12-31 | $593 |
Employer contributions (assets) at beginning of year | 2012-12-31 | $190 |
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers | 2012-12-31 | $25,658,982 |
Contract administrator fees | 2012-12-31 | $48,588 |
Was the provided the required notice or one of the exceptions to providing the black out period notice applied under 29 CFR 2520.101-3 | 2012-12-31 | No |
Did the plan have assets held for investment | 2012-12-31 | Yes |
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser | 2012-12-31 | No |
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC | 2012-12-31 | No |
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d) | 2012-12-31 | Yes |
Opinion of an independent qualified public accountant for this plan | 2012-12-31 | Disclaimer |
Accountancy firm name | 2012-12-31 | MCGLADREY LLP |
Accountancy firm EIN | 2012-12-31 | 420714325 |
2011 : PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2011 401k financial data | ||
Total unrealized appreciation/depreciation of assets | 2011-12-31 | $0 |
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2011-12-31 | $0 |
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2011-12-31 | $0 |
Total income from all sources (including contributions) | 2011-12-31 | $35,744,843 |
Total loss/gain on sale of assets | 2011-12-31 | $0 |
Total of all expenses incurred | 2011-12-31 | $20,896,280 |
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2011-12-31 | $20,849,042 |
Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2011-12-31 | $37,514,814 |
Value of total assets at end of year | 2011-12-31 | $295,268,369 |
Value of total assets at beginning of year | 2011-12-31 | $280,419,806 |
Total of administrative expenses incurred including professional, contract, advisory and management fees | 2011-12-31 | $47,238 |
Total interest from all sources | 2011-12-31 | $160,117 |
Total dividends received (eg from common stock, registered investment company shares) | 2011-12-31 | $7,108,831 |
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year | 2011-12-31 | No |
Total dividends received from registered investment company shares (eg mutual funds) | 2011-12-31 | $7,108,831 |
Was this plan covered by a fidelity bond | 2011-12-31 | Yes |
Value of fidelity bond cover | 2011-12-31 | $6,000,000 |
If this is an individual account plan, was there a blackout period | 2011-12-31 | No |
Were there any nonexempt tranactions with any party-in-interest | 2011-12-31 | No |
Contributions received from participants | 2011-12-31 | $26,721,718 |
Participant contributions at end of year | 2011-12-31 | $3,719,099 |
Participant contributions at beginning of year | 2011-12-31 | $3,362,893 |
Participant contributions at end of year | 2011-12-31 | $1,456 |
Participant contributions at beginning of year | 2011-12-31 | $373 |
Income. Received or receivable in cash from other sources (including rollovers) | 2011-12-31 | $1,902,439 |
Value of other receiveables (less allowance for doubtful accounts) at end of year | 2011-12-31 | $0 |
Value of other receiveables (less allowance for doubtful accounts) at beginning of year | 2011-12-31 | $0 |
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser | 2011-12-31 | No |
Value of net income/loss | 2011-12-31 | $14,848,563 |
Value of net assets at end of year (total assets less liabilities) | 2011-12-31 | $295,268,369 |
Value of net assets at beginning of year (total assets less liabilities) | 2011-12-31 | $280,419,806 |
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond) | 2011-12-31 | No |
Were any loans by the plan or fixed income obligations due to the plan in default | 2011-12-31 | No |
Were any leases to which the plan was party in default or uncollectible | 2011-12-31 | No |
Value of interest in registered invesment companies (eg mutual funds) at end of year | 2011-12-31 | $267,575,759 |
Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2011-12-31 | $254,355,775 |
Interest on participant loans | 2011-12-31 | $160,117 |
Value of interest in common/collective trusts at end of year | 2011-12-31 | $23,971,865 |
Value of interest in common/collective trusts at beginning of year | 2011-12-31 | $22,700,662 |
Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2011-12-31 | $-9,231,477 |
Net investment gain or loss from common/collective trusts | 2011-12-31 | $192,558 |
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets | 2011-12-31 | No |
Was there a failure to transmit to the plan any participant contributions | 2011-12-31 | No |
Has the plan failed to provide any benefit when due under the plan | 2011-12-31 | No |
Contributions received in cash from employer | 2011-12-31 | $8,890,657 |
Employer contributions (assets) at end of year | 2011-12-31 | $190 |
Employer contributions (assets) at beginning of year | 2011-12-31 | $103 |
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers | 2011-12-31 | $20,849,042 |
Contract administrator fees | 2011-12-31 | $47,238 |
Was the provided the required notice or one of the exceptions to providing the black out period notice applied under 29 CFR 2520.101-3 | 2011-12-31 | No |
Did the plan have assets held for investment | 2011-12-31 | Yes |
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser | 2011-12-31 | No |
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC | 2011-12-31 | No |
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d) | 2011-12-31 | Yes |
Opinion of an independent qualified public accountant for this plan | 2011-12-31 | Disclaimer |
Accountancy firm name | 2011-12-31 | MCGLADREY LLP |
Accountancy firm EIN | 2011-12-31 | 420714325 |
2010 : PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2010 401k financial data | ||
Total unrealized appreciation/depreciation of assets | 2010-12-31 | $0 |
Total transfer of assets from this plan | 2010-12-31 | $1,798,927 |
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2010-12-31 | $0 |
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities) | 2010-12-31 | $0 |
Total income from all sources (including contributions) | 2010-12-31 | $65,288,311 |
Total loss/gain on sale of assets | 2010-12-31 | $0 |
Total of all expenses incurred | 2010-12-31 | $14,008,033 |
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others | 2010-12-31 | $13,855,143 |
Expenses. Certain deemed distributions of participant loans | 2010-12-31 | $108,865 |
Total contributions o plan (from employers,participants, others, non cash contrinutions) | 2010-12-31 | $35,296,233 |
Value of total assets at end of year | 2010-12-31 | $280,419,806 |
Value of total assets at beginning of year | 2010-12-31 | $230,938,455 |
Total of administrative expenses incurred including professional, contract, advisory and management fees | 2010-12-31 | $44,025 |
Total interest from all sources | 2010-12-31 | $154,743 |
Total dividends received (eg from common stock, registered investment company shares) | 2010-12-31 | $4,673,551 |
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year | 2010-12-31 | No |
Total dividends received from registered investment company shares (eg mutual funds) | 2010-12-31 | $4,673,551 |
Was this plan covered by a fidelity bond | 2010-12-31 | Yes |
Value of fidelity bond cover | 2010-12-31 | $6,000,000 |
If this is an individual account plan, was there a blackout period | 2010-12-31 | No |
Were there any nonexempt tranactions with any party-in-interest | 2010-12-31 | No |
Contributions received from participants | 2010-12-31 | $25,444,957 |
Participant contributions at end of year | 2010-12-31 | $3,362,893 |
Participant contributions at beginning of year | 2010-12-31 | $2,702,578 |
Participant contributions at end of year | 2010-12-31 | $373 |
Participant contributions at beginning of year | 2010-12-31 | $21,729 |
Income. Received or receivable in cash from other sources (including rollovers) | 2010-12-31 | $1,223,076 |
Value of other receiveables (less allowance for doubtful accounts) at end of year | 2010-12-31 | $0 |
Value of other receiveables (less allowance for doubtful accounts) at beginning of year | 2010-12-31 | $0 |
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser | 2010-12-31 | No |
Value of net income/loss | 2010-12-31 | $51,280,278 |
Value of net assets at end of year (total assets less liabilities) | 2010-12-31 | $280,419,806 |
Value of net assets at beginning of year (total assets less liabilities) | 2010-12-31 | $230,938,455 |
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond) | 2010-12-31 | No |
Were any loans by the plan or fixed income obligations due to the plan in default | 2010-12-31 | No |
Were any leases to which the plan was party in default or uncollectible | 2010-12-31 | No |
Value of interest in registered invesment companies (eg mutual funds) at end of year | 2010-12-31 | $254,355,775 |
Value of interest in registered invesment companies (eg mutual funds) at beginning of year | 2010-12-31 | $205,959,327 |
Interest on participant loans | 2010-12-31 | $154,743 |
Value of interest in common/collective trusts at end of year | 2010-12-31 | $22,700,662 |
Value of interest in common/collective trusts at beginning of year | 2010-12-31 | $22,249,542 |
Net investment gain/loss from registered investment companies (e.g. mutual funds) | 2010-12-31 | $24,977,684 |
Net investment gain or loss from common/collective trusts | 2010-12-31 | $186,100 |
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets | 2010-12-31 | No |
Was there a failure to transmit to the plan any participant contributions | 2010-12-31 | No |
Has the plan failed to provide any benefit when due under the plan | 2010-12-31 | No |
Contributions received in cash from employer | 2010-12-31 | $8,628,200 |
Employer contributions (assets) at end of year | 2010-12-31 | $103 |
Employer contributions (assets) at beginning of year | 2010-12-31 | $5,279 |
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers | 2010-12-31 | $13,855,143 |
Contract administrator fees | 2010-12-31 | $44,025 |
Was the provided the required notice or one of the exceptions to providing the black out period notice applied under 29 CFR 2520.101-3 | 2010-12-31 | No |
Did the plan have assets held for investment | 2010-12-31 | Yes |
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser | 2010-12-31 | No |
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC | 2010-12-31 | No |
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d) | 2010-12-31 | Yes |
Opinion of an independent qualified public accountant for this plan | 2010-12-31 | Disclaimer |
Accountancy firm name | 2010-12-31 | MCGLADREY & PULLEN, LLP |
Accountancy firm EIN | 2010-12-31 | 420714325 |
2022: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2022 form 5500 responses | ||
---|---|---|
2022-01-01 | Type of plan entity | Single employer plan |
2022-01-01 | Submission has been amended | No |
2022-01-01 | This submission is the final filing | No |
2022-01-01 | This return/report is a short plan year return/report (less than 12 months) | No |
2022-01-01 | Plan is a collectively bargained plan | No |
2022-01-01 | Plan funding arrangement – Trust | Yes |
2022-01-01 | Plan benefit arrangement - Trust | Yes |
2021: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2021 form 5500 responses | ||
2021-01-01 | Type of plan entity | Single employer plan |
2021-01-01 | Submission has been amended | No |
2021-01-01 | This submission is the final filing | No |
2021-01-01 | This return/report is a short plan year return/report (less than 12 months) | No |
2021-01-01 | Plan is a collectively bargained plan | No |
2021-01-01 | Plan funding arrangement – Trust | Yes |
2021-01-01 | Plan benefit arrangement - Trust | Yes |
2020: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2020 form 5500 responses | ||
2020-01-01 | Type of plan entity | Single employer plan |
2020-01-01 | Submission has been amended | No |
2020-01-01 | This submission is the final filing | No |
2020-01-01 | This return/report is a short plan year return/report (less than 12 months) | No |
2020-01-01 | Plan is a collectively bargained plan | No |
2020-01-01 | Plan funding arrangement – Trust | Yes |
2020-01-01 | Plan benefit arrangement - Trust | Yes |
2019: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2019 form 5500 responses | ||
2019-01-01 | Type of plan entity | Single employer plan |
2019-01-01 | Submission has been amended | No |
2019-01-01 | This submission is the final filing | No |
2019-01-01 | This return/report is a short plan year return/report (less than 12 months) | No |
2019-01-01 | Plan is a collectively bargained plan | No |
2019-01-01 | Plan funding arrangement – Trust | Yes |
2019-01-01 | Plan benefit arrangement - Trust | Yes |
2018: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2018 form 5500 responses | ||
2018-01-01 | Type of plan entity | Single employer plan |
2018-01-01 | Submission has been amended | No |
2018-01-01 | This submission is the final filing | No |
2018-01-01 | This return/report is a short plan year return/report (less than 12 months) | No |
2018-01-01 | Plan is a collectively bargained plan | No |
2018-01-01 | Plan funding arrangement – Trust | Yes |
2018-01-01 | Plan benefit arrangement - Trust | Yes |
2017: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2017 form 5500 responses | ||
2017-01-01 | Type of plan entity | Single employer plan |
2017-01-01 | Submission has been amended | No |
2017-01-01 | This submission is the final filing | No |
2017-01-01 | This return/report is a short plan year return/report (less than 12 months) | No |
2017-01-01 | Plan is a collectively bargained plan | No |
2017-01-01 | Plan funding arrangement – Trust | Yes |
2017-01-01 | Plan benefit arrangement - Trust | Yes |
2016: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2016 form 5500 responses | ||
2016-01-01 | Type of plan entity | Single employer plan |
2016-01-01 | Submission has been amended | No |
2016-01-01 | This submission is the final filing | No |
2016-01-01 | This return/report is a short plan year return/report (less than 12 months) | No |
2016-01-01 | Plan is a collectively bargained plan | No |
2016-01-01 | Plan funding arrangement – Trust | Yes |
2016-01-01 | Plan benefit arrangement - Trust | Yes |
2015: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2015 form 5500 responses | ||
2015-01-01 | Type of plan entity | Single employer plan |
2015-01-01 | Submission has been amended | No |
2015-01-01 | This submission is the final filing | No |
2015-01-01 | This return/report is a short plan year return/report (less than 12 months) | No |
2015-01-01 | Plan is a collectively bargained plan | No |
2015-01-01 | Plan funding arrangement – Trust | Yes |
2015-01-01 | Plan benefit arrangement - Trust | Yes |
2014: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2014 form 5500 responses | ||
2014-01-01 | Type of plan entity | Single employer plan |
2014-01-01 | Submission has been amended | No |
2014-01-01 | This submission is the final filing | No |
2014-01-01 | This return/report is a short plan year return/report (less than 12 months) | No |
2014-01-01 | Plan is a collectively bargained plan | No |
2014-01-01 | Plan funding arrangement – Trust | Yes |
2014-01-01 | Plan benefit arrangement - Trust | Yes |
2013: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2013 form 5500 responses | ||
2013-01-01 | Type of plan entity | Single employer plan |
2013-01-01 | Submission has been amended | No |
2013-01-01 | This submission is the final filing | No |
2013-01-01 | This return/report is a short plan year return/report (less than 12 months) | No |
2013-01-01 | Plan is a collectively bargained plan | No |
2013-01-01 | Plan funding arrangement – Trust | Yes |
2013-01-01 | Plan benefit arrangement - Trust | Yes |
2012: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2012 form 5500 responses | ||
2012-01-01 | Type of plan entity | Single employer plan |
2012-01-01 | Submission has been amended | No |
2012-01-01 | This submission is the final filing | No |
2012-01-01 | This return/report is a short plan year return/report (less than 12 months) | No |
2012-01-01 | Plan is a collectively bargained plan | No |
2012-01-01 | Plan funding arrangement – Trust | Yes |
2012-01-01 | Plan benefit arrangement - Trust | Yes |
2011: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2011 form 5500 responses | ||
2011-01-01 | Type of plan entity | Single employer plan |
2011-01-01 | Submission has been amended | No |
2011-01-01 | This submission is the final filing | No |
2011-01-01 | This return/report is a short plan year return/report (less than 12 months) | No |
2011-01-01 | Plan is a collectively bargained plan | No |
2011-01-01 | Plan funding arrangement – Trust | Yes |
2011-01-01 | Plan benefit arrangement - Trust | Yes |
2009: PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC RETIREMENT SAVINGS PLAN 2009 form 5500 responses | ||
2009-01-01 | Type of plan entity | Single employer plan |
2009-01-01 | Submission has been amended | No |
2009-01-01 | This submission is the final filing | No |
2009-01-01 | This return/report is a short plan year return/report (less than 12 months) | No |
2009-01-01 | Plan is a collectively bargained plan | No |
2009-01-01 | Plan funding arrangement – Trust | Yes |
2009-01-01 | Plan benefit arrangement - Trust | Yes |